Aardvark Therapeutics (AARD) Stock Price, News & Analysis

Company Overview

Aardvark Therapeutics, Inc. is a clinical-stage biopharmaceutical company based in Cambridge, Massachusetts, specializing in the discovery and development of small-molecule modulators of the retinoic acid receptor–related orphan receptor gamma (RORγ). RORγ plays a central role in T-helper 17 (Th17) cell differentiation and inflammatory processes. By targeting this transcription factor, Aardvark aims to address a range of autoimmune and immune-mediated diseases.

The company’s lead programs consist of selective RORγ inverse agonists designed to suppress pathogenic Th17-driven responses in conditions such as psoriasis, inflammatory bowel disease and other chronic inflammatory disorders. Leveraging a proprietary screening platform, structural biology capabilities and medicinal chemistry expertise, Aardvark has advanced multiple preclinical candidates toward IND-enabling studies. These programs are supported by in vitro and in vivo pharmacology, biomarker development and toxicology assessments conducted at the company’s Cambridge research facilities.

Founded by a team of immunology and drug-development veterans, Aardvark Therapeutics is led by President and CEO Marshall Bolog, Ph.D. The leadership team combines translational pharmacology, clinical development and regulatory affairs expertise to guide the company’s pipeline through preclinical and early clinical stages. Aardvark pursues strategic collaborations with academic institutions and industry partners to enhance its RORγ portfolio and is positioned to advance its therapeutic candidates into human trials while exploring global licensing and development opportunities.

Key Stats

• Today's Range: $7.88 to $8.20
• 50-Day Range: $7.91 to $14.70
• 52-Week Range: $4.88 to $19.58
• Volume: 59,436 shs
• Average Volume: 89,693 shs
• Market Capitalization: $173.17 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $32.60
• Consensus Rating: Buy

AARD Stock Analysis - Frequently Asked Questions

How have AARD shares performed this year?

Aardvark Therapeutics' stock was trading at $13.30 at the start of the year. Since then, AARD stock has decreased by 40.5% and is now trading at $7.91.

How were Aardvark Therapeutics' earnings last quarter?

Aardvark Therapeutics, Inc. (NASDAQ:AARD) announced its quarterly earnings data on Wednesday, August, 13th. The company reported ($0.66) earnings per share for the quarter, missing the consensus estimate of ($0.52) by $0.14.

When did Aardvark Therapeutics IPO?

Aardvark Therapeutics (AARD) raised $100 million in an IPO on Friday, February 14th 2025. The company issued 5,900,000 shares at $16.00-$18.00 per share. Morgan Stanley, BofA Securities, Cantor and RBC Capital Markets served as the underwriters for the IPO.

When did Aardvark Therapeutics' lock-up period expire?

Aardvark Therapeutics's lock-up period expired on Tuesday, August 12th. Aardvark Therapeutics had issued 5,888,000 shares in its initial public offering on February 13th. The total size of the offering was $94,208,000 based on an initial share price of $16.00. Since the expiration of Aardvark Therapeutics' lock-up period, restrictions preventing company insiders and major shareholders from selling shares in the company have been lifted.

Who are Aardvark Therapeutics' major shareholders?

Top institutional shareholders of Aardvark Therapeutics include Adage Capital Partners GP L.L.C. (0.81%), Geode Capital Management LLC (0.63%), Bank of America Corp DE (0.04%) and New York State Common Retirement Fund (0.03%). Insiders that own company stock include Tien-Li Lee and Nelson Sun.
View institutional ownership trends.

How do I buy shares of Aardvark Therapeutics?

Shares of AARD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Company Calendar

• Last Earnings: 8/13/2025
• Today: 9/10/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:AARD
• Previous Symbol: NASDAQ:AARD
• CIK: 1774857
• Web: N/A
• Phone: (858) 225-7696
• Fax: N/A
• Employees: 18
• Year Founded: N/A

Price Target and Rating

• Average Price Target for Aardvark Therapeutics: $32.60
• High Price Target: $50.00
• Low Price Target: $19.00
• Potential Upside/Downside: +312.1%
• Consensus Rating: Buy
• Rating Score (0-4): 3.00
• Research Coverage: 5 Analysts

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 14.04
• Quick Ratio: 14.04

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: N/A
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: 21,700,000
• Free Float: N/A
• Market Cap: $171.65 million
• Optionable: N/A
• Beta: N/A